Mackay Shields LLC’s Cardlytics CDLX Stock Holding History

Mackay Shields LLC’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-450	Closed	-$642K	–	1506
2020 Q4	$642K	Buy	+450	New	+$480K	﹤0.01%	1192

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Mackay Shields LLC's CDLX Position: Q1 2021 in Review

Mackay Shields LLC sold out of Cardlytics (CDLX) in Q1 2021, closing a stake of 450 shares — an estimated $642K sold.

Mackay Shields LLC first reported a position in CDLX in Q4 2020 and held it in 1 quarter. The position peaked at $642K in Q4 2020. 204 funds tracked by Wall St. Rank hold CDLX as of Q1 2021.

Mackay Shields LLC reported no remaining Cardlytics position as of Q1 2021 after selling out during the quarter.
Mackay Shields LLC sold 450 Cardlytics shares in Q1 2021, an estimated $642K.
Mackay Shields LLC first reported a position in Cardlytics in Q4 2020 and held it in 1 quarter.
Mackay Shields LLC's Cardlytics position peaked at $642K in Q4 2020.
204 funds tracked by Wall St. Rank held Cardlytics as of Q1 2021.

Based on Mackay Shields LLC's 13F filing for Q1 2021, filed 14 May 2021.